Pharming Group NV · EURONEXT:PHARM
Pharming Group NV — Shareholder Meeting (May 2004)
41 slides from Pharming Group NV's shareholder meeting presentation, May 18, 2004
Slide 1: Annual General Meeting of Shareholders
Annual General Meeting of Shareholders May 18, 2004 Pharming, AGM 18May04
Slide 2: Strategic Evolution of Pharming
Strategic Evolution of Pharming 2002 2003 2004 2005 People Financial Products & Profits Turnaround Partners Pharming, AGM 18May04 2
Slide 3: Pharming Turnaround
Pharming Turnaround End 2001 End 2002 Company in receivership Exit receivership No BOSD New management and BOSD Annual loss € 55 million Annual loss € 1 million Negative equity Equity > € 11 million Debt > € 24 million Debt € 5 million Penalty bench Euronext Listing on Euronext Uncertainty in partne
Slide 4: Pharming Turnaround May 2004
Pharming Turnaround May 2004 • Strong cash position with € 30 million sucessfully raised via private placement in February 2004 • Elimination of all debt • Market Cap now more than € 100 million • Focused research spending continues • Lead product recombinant human C1 inhibitor now in pivotal Phase
Slide 5: Pharming
PHARMING Pharming, AGM 18May04
Slide 6: Consolidated balance sheet
Consolidated balance sheet 31-mrt-04 31-dec-03 31-dec-02 (unaudited) (audited) (audited) All amounts EURx1,000 ASSETS Non-current assets 6,244 6,369 8,278 Current assets Inventories + other current assets 3,888 3,643 7,703 Cash and cash equivalents 28,314 2,699 542 Total current assets 32,202 6,342
Slide 7: Consolidated statement of income
Consolidated statement of income Year ended December 31, Q1-2004 2003 2002 unaudited audited audited All amounts EURx1,000 REVENUES 55 432 2,898 COSTS AND EXPENSES Costs normal operations 2,203 10,706 8,273 Success fee, restructuring, reorganization 1,005 531 (4,174) TOTAL COSTS AND EXPENSES 3,208 1
Slide 8: Consolidated statement of cash flow
Consolidated statement of cash flow Year ended December 31, Q1-2004 2003 2002 unaudited audited audited All amounts EURx1,000 Net loss (3,126) (10,978) (927) Non-cash increases in equity 1,005 750 5,918 Non-cash movement of non-current assets 234 1,381 1,453 Other non-cash items 66 (16) (6,116) Chan
Slide 9: Pharming share - historic price movement
Pharming share - historic price movement 2,5 2 1,5 Euro 1 0,5 0 n 03 b03 rt03 r03 i03 n03 ul03 g03 p03 t03 v03 c03 n04 b04 rt04 r04 ja fe m ap me ju j k p au se o no de ja fe m a Pharming, AGM 18May04 9
Slide 10: Pharming
PHARMING Pharming, AGM 18May04 10
Slide 11: Highlights of 2004
Highlights of 2004 • Completion of financial turnaround • First partnership on rhC1INH • Initiation of Phase III trial for rhC1INH • Acceleration of development of other products in portfolio • Improvement of IP-position • Improvement of organizational structure Pharming, AGM 18May04 11
Slide 12: Pharming
PHARMING Pharming, AGM 18May04 12
Slide 13: Protein Production Technology
Protein Production Technology Generate Develop Purify Formulate and Expand genetic founder / protein deliver protein herd constructs mini-herd from milk therapeutic Pharming, AGM 18May04 13
Slide 14: Protein Production Technology
Protein Production Technology Pharming Technology • Large scale, cost-effective production of complex proteins for human therapeutic use • Applied to product development (rhC1INH; rhFIB; rhCOL; rhLF) Role of Intellectual Property (IP) • Provides Freedom to Operate • Provides entry barrier • Protecti
Slide 15: Enhancing Technology and IP position
Enhancing Technology and IP position Controlling interest in ProBio • Broad IP portfolio, strongly synergistic to Pharming IP • Presence in Australasia (incl. Singapore) • Stake in CRC (Melbourne), providing technology, IP, commercial opportunities • Licensing and partnering discussions ongoing Broa
Slide 16: Enhancing Technology and IP position
Enhancing Technology and IP position Combined effect ProBio / Infigen • More commercial opportunities for products and technology • Core protein production technology and IP enhanced • Synergistic with GTC cross-license • Product development accelerated Pharming well positioned for future Pharming,
Slide 17: Pharming
PHARMING Pharming, AGM 18May04 17
Slide 18: What is HAE
What is HAE C1 inhibitor deficiency Recurrent activation of contact and complement systems Vasoactieve peptides Episodes of swelling Pharming, AGM 18May04 18
Slide 19: Pharming, AGM 18May04
Pharming, AGM 18May04 19
Slide 20: RhC1INH for HAE (Prevalence: 30,000)
RhC1INH for HAE (Prevalance: 30,000) Population (thousands) 2003 2004 2005 2006 2007 2008 2009 2010 North America 322.028 324.078 326.128 328.178 330.228 332.278 334.328 336.378 Europe 402.803 404.903 407.003 409.103 411.203 413.303 415.403 417.503 Total 724.831 728.981 733.131 737.281 741.431 745.5
Slide 21: Clinical Development
Clinical Development Open label Phase II/III design Base Study Pre-study Attack Measurements population population assessments treatment Inclusion/ exclusion Time Pharming, AGM 18May04 21
Slide 22: Study Methodology Phase III Europe
Study Methodology Phase III Europe Randomized double-blind placebo controlled clinical trial Treatment rhC1INH A Measurements Base Research Pre-study Rando- Contrast Effect population Population assessments mization Inclusion/ Treatment Placebo B Measurements exclusion Time Pharming, AGM 18May04 22
Slide 23: Study Methodology Phase II/III USA
Study Methodology Phase II/III USA Treatment 100 U/Kg A Measurements Contrast Effect Base Research Pre-study Rando- Treatment Placebo B Measurements population Population assessments mization Inclusion/ Contrast Effect exclusion 50 U/kg C Treatment Measurements • Interim analysis • Open label 100 U/
Slide 24: Pharming
Pharming Powered by biotechnology Focused on patients Pharming, AGM 18May04 24
Slide 25: Pharming
PHARMING Pharming, AGM 18May04 25
Slide 26: Recombinant human lactoferrin
Recombinant human lactoferrin Cristal analysis by Harrie van Veen (Pharming) Jan PieterAbrahams (Gorlaeus laboratory) Conclusion rhLF identical to nhLF Pharming, AGM 18May04 26
Slide 27: Human lactoferrin properties
Human lactoferrin properties • Protein with anti-infective, anti-inflammatory, pro-biotic and immuno-modulating properties • Lactoferrin is present in human milk, tears, mucosal secretions of GI-tract and lungs Pharming, AGM 18May04 27
Slide 28: Project update
Project update • GRAS study will be revived • Package for partnering in Asia and USA Sperm, purification protocols, purified material (parenteral/oral grade), pre-clinical and clinical study package, implementation strategy (herd generation, know-how and knowledge) • Indication area’s Healthfoods In
Slide 29: Recombinant human lactoferrin - the product(s)
Recombinant human lactoferrin-the product(s) Oral Parenteral Pharming, AGM 18May04 29
Slide 30: Market potential
Market potential • Nutraceutical Northeast-Asia total market: China billion$ 10.9 (1998) 20% Current bLF market 40 metric tons value Taiwan million$ 30-50 6% • Ophthalmic market Korea USA; million$ 200 Japan 9% 65% Pharming, AGM 18May04 30
Slide 31: Current activities in rhLF project
Current activities in rhLF project • Strategy: further development of the project and partner for indications close to market • Continue research with partners (ongoing) • Identification of partners for market(s) • Finalize GRAS-toxicology study • Cattle breeding Pharming, AGM 18May04 31
Slide 32: Recombinant human lactoferrin
Recombinant human lactoferrin Value to develop Pharming, AGM 18May04 32
Slide 33: Pharming
PHARMING Pharming, AGM 18May04 33
Slide 34: Pharming US (Wisconsin)
Pharming US (Wisconsin) • State of the art facility • 7 employees • Key products in develop. • Largest transgenic herd • Capacity to produce proteins for pre-clinical/ clinical trials • Future capacity of over 3000 kg Pharming, AGM 18May04 34
Slide 35: Financing and Investors - US
Financing and Investors - US New Investors • Roadshow in the US for the last financing round • Participation from US investors (over 15% of financing round) Institutional Support • Introduced company to select group of institutional funds • Identified US investor relation group • New research covera
Slide 36: Pharming US
Pharming US Focus on Profitability and Products Profitability • Reduced costs by over 25% through restructuring of operations • Increase revenues through partnerships and grants Local Support • WI State - forgiveness of loan, exploring new opportunities • Employees - participation in salary deferral
Slide 37: Recombinant Human Fibrinogen and Collagen
Recombinant Human Fibrinogen and Collagen Recombinant Human Fibrinogen Collagen Technical Platforms available for production Cattle Cattle & Rabbit Expression level High High Comparison to natural human protein Similar Similar Purified product Available Available Business Market for intermediate pro
Slide 38: Recombinant Tissue Sealant
Recombinant Tissue Sealant • Stop severe blood loss caused by trauma or major surgery • Replace current plasma derived fibrin sealants • Market segments targeted for development Orthopedic Surgery (Spinal fusion and total hip/knee replacement) Burns requiring skin grafting • Current status Pre-clini
Slide 39: Business and Product Development rhFIB and rhCOL
Business and Product Development rhFIB and rhCOL Business Strategy • Supply of products as intermediate for third party product development • Identify surgical or orphan indications with short development timelines • Establish partnerships • Deliver proprietary products for these indications Product
Slide 40: Pharming
PHARMING Pharming, AGM 18May04 40
Slide 41: Strategic Evolution of Pharming
Strategic Evolution of Pharming 2002 2003 2004 2005 People Financial Products & Profits Turnaround Partners Pharming, AGM 18May04 41